CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Rochester, Minnesota, United States and 164 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
Rochester, Minnesota, United States and 23 other locations
This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...
Phase 2
Rochester, Minnesota, United States and 27 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Rochester, Minnesota, United States and 43 other locations
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML...
Phase 2
Rochester, Minnesota, United States and 17 other locations
menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....
Phase 1, Phase 2
Rochester, Minnesota, United States and 51 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia...
Phase 1
Rochester, Minnesota, United States and 22 other locations
in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with veneto...
Phase 1
Rochester, Minnesota, United States and 11 other locations
(CAR) T cells), in adult patients with relapsed or refractory acute myeloid leukemia (AML), Minimal Residual Dise ...
Phase 1
Rochester, Minnesota, United States and 1 other location
profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelod...
Phase 1, Phase 2
Rochester, Minnesota, United States and 3 other locations
Clinical trials
Research sites
Resources
Legal